Graham Capital Management L.P. Trims Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Graham Capital Management L.P. decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 34.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,350 shares of the biopharmaceutical company's stock after selling 1,260 shares during the quarter. Graham Capital Management L.P.'s holdings in Alnylam Pharmaceuticals were worth $553,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the stock. Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter worth $1,045,822,000. Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $577,941,000. Capital Research Global Investors lifted its stake in shares of Alnylam Pharmaceuticals by 32.9% during the 4th quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after buying an additional 1,724,610 shares in the last quarter. T. Rowe Price Investment Management Inc. boosted its holdings in Alnylam Pharmaceuticals by 39.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock worth $1,031,705,000 after buying an additional 1,245,195 shares during the period. Finally, Marshall Wace LLP grew its stake in Alnylam Pharmaceuticals by 496.6% in the 4th quarter. Marshall Wace LLP now owns 378,649 shares of the biopharmaceutical company's stock valued at $89,100,000 after buying an additional 315,182 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company's stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total value of $389,585.16. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. The trade was a 11.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total transaction of $362,246.40. Following the completion of the transaction, the executive vice president now owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company's stock.

Analyst Ratings Changes

ALNY has been the topic of several recent research reports. Redburn Atlantic initiated coverage on Alnylam Pharmaceuticals in a research report on Monday, March 31st. They set a "buy" rating and a $353.00 target price on the stock. HC Wainwright reiterated a "buy" rating and set a $500.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $280.00 to $328.00 in a research report on Monday, March 24th. Stifel Nicolaus boosted their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research note on Monday, March 31st. Finally, Scotiabank boosted their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $319.17.

Alnylam Pharmaceuticals Price Performance

ALNY traded up $6.55 during midday trading on Monday, hitting $291.86. The stock had a trading volume of 929,466 shares, compared to its average volume of 911,976. The company has a market cap of $38.06 billion, a P/E ratio of -134.50 and a beta of 0.17. The business has a fifty day moving average of $253.73 and a 200 day moving average of $253.49. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 1 year low of $146.79 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. The company's revenue was up 20.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.16) earnings per share. As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.